Albireo Pharma Inc.

32.12-0.8000-2.43%Vol 15.97K1Y Perf 82.19%
Apr 16th, 2021 11:17 DELAYED
BID32.00 ASK32.30
Open32.71 Previous Close32.92
Pre-Market- After-Market-
 - -%  - -
Target Price
73.00 
Analyst Rating
Strong Buy 1.00
Potential %
125.03 
Finscreener Ranking
★★★★+     56.53
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★+     53.49
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★     53.51
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap613.94M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
47.25 
Earnings Date
6th May 2021

Today's Price Range

32.1233.58

52W Range

17.0049.00

5 Year PE Ratio Range

-6.00-1.60

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
0.12%
1 Month
-10.66%
3 Months
-7.53%
6 Months
-4.97%
1 Year
82.19%
3 Years
-0.54%
5 Years
188.77%
10 Years
-87.64%

TickerPriceChg.Chg.%
ALBO32.12-0.8000-2.43
AAPL133.93-0.5700-0.42
GOOG2 294.74-1.9200-0.08
MSFT259.520.02000.01
XOM56.95-0.0300-0.05
WFC43.080.84001.99
JNJ161.240.85000.53
FB306.16-1.6600-0.54
GE13.46-0.0900-0.66
JPM153.221.05000.69
Financial StrengthValueIndustryS&P 500US Markets
9.90
10.40
0.05
0.05
-8.50
Leverage Ratio 1.70
ProfitabilityValueIndustryS&P 500US Markets
-
-673.90
-672.60
-484 530.00
-
RevenueValueIndustryS&P 500US Markets
6.76M
0.35
-11.09
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020-1.90-1.3031.58
Q03 2020-1.48-1.96-32.43
Q02 2020-1.65-1.3816.36
Q01 2020-1.39-2.23-60.43
Q04 2019-1.58-0.5763.92
Q03 2019-1.55-1.73-11.61
Q02 2019-1.44-1.356.25
Q01 2019-1.37-1.39-1.46
Earnings Per EndEstimateRevision %Trend
3/2021 QR-1.7214.43Positive
6/2021 QR-1.7418.69Positive
12/2021 FY-7.0319.29Positive
12/2022 FY-4.490.66Positive
Next Report Date6th May 2021
Estimated EPS Next Report-1.72
Estimates Count7
EPS Growth Next 5 Years %-
Volume Overview
Volume15.97K
Shares Outstanding19.11M
Trades Count362
Dollar Volume8.48M
Avg. Volume169.33K
Avg. Weekly Volume125.78K
Avg. Monthly Volume147.16K
Avg. Quarterly Volume168.43K

Albireo Pharma Inc. (NASDAQ: ALBO) stock closed at 32.92 per share at the end of the most recent trading day (a 1.64% change compared to the prior day closing price) with a volume of 195.66K shares and market capitalization of 613.94M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 90 people. Albireo Pharma Inc. CEO is Ronald H.W. Cooper.

The one-year performance of Albireo Pharma Inc. stock is 82.19%, while year-to-date (YTD) performance is -12.24%. ALBO stock has a five-year performance of 188.77%. Its 52-week range is between 17 and 49, which gives ALBO stock a 52-week price range ratio of 47.25%

Albireo Pharma Inc. currently has a PE ratio of -5.00, a price-to-book (PB) ratio of 3.55, a price-to-sale (PS) ratio of 90.32, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -46.26%, a ROC of -48.75% and a ROE of -76.16%. The company’s profit margin is -%, its EBITDA margin is -672.60%, and its revenue ttm is $6.76 Million , which makes it $0.35 revenue per share.

Of the last four earnings reports from Albireo Pharma Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.72 for the next earnings report. Albireo Pharma Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Albireo Pharma Inc. is Strong Buy (1), with a target price of $73, which is +125.03% compared to the current price. The earnings rating for Albireo Pharma Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Albireo Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Albireo Pharma Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.86, ATR14 : 2.08, CCI20 : -88.48, Chaikin Money Flow : -0.18, MACD : -1.43, Money Flow Index : 35.63, ROC : -3.74, RSI : 50.51, STOCH (14,3) : 22.94, STOCH RSI : 1.00, UO : 34.48, Williams %R : -77.06), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Albireo Pharma Inc. in the last 12-months were: Jan P. Mattsson (Option Excercise at a value of $39 330), Jan P. Mattsson (Sold 41 470 shares of value $1 615 184 ), Jason G. Duncan (Option Excercise at a value of $84 140), Jason G. Duncan (Sold 4 382 shares of value $193 072 ), Martha Carter (Option Excercise at a value of $886 380), Martha Carter (Sold 40 000 shares of value $1 669 550 ), Pamela Stephenson (Sold 1 308 shares of value $45 171 ), Patrick Taylor Horn (Sold 382 shares of value $10 854 ), Simon N.R. Harford (Sold 292 shares of value $9 815 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (100.00 %)
7 (100.00 %)
7 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Albireo Pharma Inc.

Albireo Pharma Inc is a development-stage pharmaceutical company. It engages in the research and development of drug reformulation technology. The company product portfolio includes Pediatric Liver, Adult Liver, and Gastrointestinal.

CEO: Ronald H.W. Cooper

Telephone: +1 857 254-5555

Address: 10 Post Office Square, South Boston 02109, MA, US

Number of employees: 90

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

73%27%

Bearish Bullish

53%47%

Bearish Bullish

59%41%

News

Stocktwits